

DESCRIPTION


Species Reactivity	Human
Specificity	Detects human VEGF-D in direct ELISAs and Western blots. In direct ELISAs, 100% cross-reactivity with mVEGF-D and less than 1% cross-reactivity with recombinant human (rh) VEGF-C is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human VEGF-D Phe93-Ser201 Accession # O43915
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Western Blot	0.1 µg/mL	Recombinant Human VEGF-D (Catalog # 622-VD)
Neutralization	Measured by its ability to neutralize VEGF-D-induced proliferation in HMVEC human microvascular endothelial cells [Achen, M. <i>et al.</i> (1998) Proc. Natl. Acad. Sci. USA 95 :548]. The Neutralization Dose (ND ₅₀) is typically 3-10 µg/mL in the presence of 1 µg/mL Recombinant Human VEGF-D.	

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> • 12 months from date of receipt, -20 to -70 °C as supplied. • 1 month, 2 to 8 °C under sterile conditions after reconstitution. • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Vascular endothelial growth factor D (VEGF-D), also known as *c-fos*-induced growth factor (FIGF), is a secreted glycoprotein of the VEGF/PDGF family. VEGFs regulate angiogenesis and lymphangiogenesis during development and tumor growth, and are characterized by eight conserved cysteine residues that form a cystine knot structure (1-3). VEGF-C and VEGF-D, which share 23% amino acid (aa) sequence identity, are uniquely expressed as preproteins that contain long N- and C-terminal propeptide extensions around the VEGF homology domain (VHD) (1, 2). Proteolytic processing of the 354 aa VEGF-D preproprotein creates a secreted proprotein. Further processing by extracellular serine proteases, such as plasmin or furin-like proprotein convertases, forms mature VEGF-D consisting of non-covalently linked 42 kDa homodimers of the 117 aa VHD (4-6). Mature human VEGF-D shares 94%, 95%, 99%, 97%, and 93% aa identity with mouse, rat, equine, canine and bovine VEGF-D, respectively (4, 5). It is expressed in adult lung, heart, muscle, and small intestine, and is most abundantly expressed in fetal lungs and skin (1-4). Mouse and human VEGF-D are ligands for VEGF Receptor 3 (VEGF R3; also called Flt-4) that are active across species and show enhanced affinity when processed (7). Processed human VEGF-D is also a ligand for VEGF R2, also called Flk-1 or KDR (7). VEGF R3 is strongly expressed in lymphatic endothelial cells and is essential for regulation of the growth and differentiation of lymphatic endothelium (1, 2). While VEGF-C is the critical ligand for VEGF R3 during embryonic lymphatic development, VEGF-D is most active in neonatal lymphatic maturation and bone growth (8-10). Both promote tumor lymphangiogenesis (11). Consonant with their activity on VEGF receptors, binding of VEGF-C and VEGF-D to neuropilins contributes to VEGF R3 signaling in lymphangiogenesis, while binding to integrin $\alpha 9 \beta 1$ mediates endothelial cell adhesion and migration (12, 13).

References:

1. Roy, H. *et al.* (2006) FEBS Lett. **580**:2879.
2. Otrrock, Z.H. *et al.* (2007) Blood Cells Mol. Dis. **38**:258.
3. Yamada, Y. *et al.* (1997) Genomics **42**:483.
4. Stacker, S.A. *et al.* (1999) J. Biol. Chem. **274**:32127.
5. McColl, B.K. *et al.* (2003) J. Exp. Med. **198**:863.
6. McColl, B.K. *et al.* (2007) FASEB J. **21**:1088.
7. Baldwin, M.E. *et al.* (2001) J. Biol. Chem. **276**:19166.
8. Baldwin, M.E. *et al.* (2005) Mol. Cell. Biol. **25**:2441.
9. Karpanen, T. *et al.* (2006) Am. J. Pathol. **169**:708.
10. Orlandini, M. *et al.* (2006) J. Biol. Chem. **281**:17961.
11. Stacker, S.A. *et al.* (2001) Nature Med. **7**:186.
12. Karpanen, T. *et al.* (2006) FASEB J. **20**:1462.
13. Vlahakis, N.E. *et al.* (2005) J. Biol. Chem. **280**:4544.